130 related articles for article (PubMed ID: 30981872)
1. Effect of molecular weight of hypromellose on mucin diffusion and oral absorption behavior of fenofibrate nanocrystal.
Ueda K; Iwai T; Sunazuka Y; Chen Z; Kato N; Higashi K; Moribe K
Int J Pharm; 2019 Jun; 564():39-47. PubMed ID: 30981872
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of the drug distribution and mucus diffusion properties of self-microemulsifying drug delivery systems on the oral absorption of fenofibrate.
Sunazuka Y; Ueda K; Higashi K; Tanaka Y; Moribe K
Int J Pharm; 2018 Jul; 546(1-2):263-271. PubMed ID: 29763688
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Investigation of Intestinal Drug Absorption Enhancement by Drug-Rich Nanodroplets Generated via Liquid-Liquid Phase Separation.
Yoshikawa E; Ueda K; Hakata R; Higashi K; Moribe K
Mol Pharm; 2024 Apr; 21(4):1745-1755. PubMed ID: 38501717
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
Wei JD; Ho HO; Chen CH; Ke WT; Chen ET; Sheu MT
J Pharm Pharmacol; 2010 Dec; 62(12):1685-96. PubMed ID: 21054394
[TBL] [Abstract][Full Text] [Related]
5. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Suys EJA; Chalmers DK; Pouton CW; Porter CJH
Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
[TBL] [Abstract][Full Text] [Related]
6. Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-milling with a superdisintegrant and an adsorbing polymer.
Azad M; Afolabi A; Bhakay A; Leonardi J; Davé R; Bilgili E
Eur J Pharm Biopharm; 2015 Aug; 94():372-85. PubMed ID: 26079832
[TBL] [Abstract][Full Text] [Related]
7. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate.
Jung HJ; Ahn HI; Park JY; Ho MJ; Lee DR; Cho HR; Park JS; Choi YS; Kang MJ
Int J Biol Macromol; 2016 Feb; 83():282-7. PubMed ID: 26642839
[TBL] [Abstract][Full Text] [Related]
8. The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals.
Imono M; Uchiyama H; Yoshida S; Miyazaki S; Tamura N; Tsutsumimoto H; Kadota K; Tozuka Y
Eur J Pharm Biopharm; 2020 Jan; 146():84-92. PubMed ID: 31816392
[TBL] [Abstract][Full Text] [Related]
9. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the Solubility of Fenofibrate by Nanocrystal Formation and Encapsulation.
Kumar R; Siril PF
AAPS PharmSciTech; 2018 Jan; 19(1):284-292. PubMed ID: 28702816
[TBL] [Abstract][Full Text] [Related]
11. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
Suys EJA; Brundel DHS; Chalmers DK; Pouton CW; Porter CJH
J Control Release; 2021 Mar; 331():45-61. PubMed ID: 33450318
[TBL] [Abstract][Full Text] [Related]
12. Fast dissolution of poorly water soluble drugs from fluidized bed coated nanocomposites: Impact of carrier size.
Azad M; Moreno J; Bilgili E; Davé R
Int J Pharm; 2016 Nov; 513(1-2):319-331. PubMed ID: 27639622
[TBL] [Abstract][Full Text] [Related]
13. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo.
Tuomela A; Liu P; Puranen J; Rönkkö S; Laaksonen T; Kalesnykas G; Oksala O; Ilkka J; Laru J; Järvinen K; Hirvonen J; Peltonen L
Int J Pharm; 2014 Jun; 467(1-2):34-41. PubMed ID: 24680962
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the surface hydrophilic properties of naproxen particles with addition of hydroxypropylmethyl cellulose and sodium dodecyl sulphate: In vitro and in vivo studies.
García-Herrero V; Torrado C; García-Rodríguez JJ; López-Sánchez A; Torrado S; Torrado-Santiago S
Int J Pharm; 2017 Aug; 529(1-2):381-390. PubMed ID: 28705616
[TBL] [Abstract][Full Text] [Related]
15. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
Buch P; Langguth P; Kataoka M; Yamashita S
J Pharm Sci; 2009 Jun; 98(6):2001-9. PubMed ID: 18855916
[TBL] [Abstract][Full Text] [Related]
16. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
[TBL] [Abstract][Full Text] [Related]
17. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
18. Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.
Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
Mol Pharm; 2016 Aug; 13(8):2787-95. PubMed ID: 27337060
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Ige PP; Baria RK; Gattani SG
Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
[TBL] [Abstract][Full Text] [Related]
20. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.
Xu Y; Wang Y; Li XM; Huang Q; Chen W; Liu R; Chen B; Wei P
Drug Dev Ind Pharm; 2014 Jul; 40(7):972-9. PubMed ID: 23692349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
